Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03477604 · ClinicalTrials.gov registry record · NA
A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)
A NA study of Peripheral Arterial Disease, sponsored by Micro Medical Solution.
- Active
- Registry status
- NA
- Development phase
- 177
- Enrollment target
- 20
- Study locations
NCT03477604: Active NA study of Peripheral Arterial Disease, sponsored by Micro Medical Solution.
NCT03477604 is a NA study of Peripheral Arterial Disease that is active but no longer recruiting, run by Micro Medical Solution. The registered enrollment target is 177 participants, below the 4,204-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03477604, a NA study of Peripheral Arterial Disease, is active but no longer recruiting, sponsored by Micro Medical Solution.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 177 participants
- Enrollment target
- 20
- Study locations
Study Summary
Randomized multicenter clinical trial consisting of two arms; one arm treated with PTA plus the MicroStent® System and one arm treated with PTA alone. Purpose to evaluate the safety and effectiveness of using the MicroStent® Peripheral Vascular Stent System, hereafter referred to as the MicroStent® System, for the treatment of infrapopliteal lesions in subjects with peripheral arterial disease.
Primary Outcome
Primary patency defined as freedom from target lesion occlusion with no clinically driven target lesion reintervention, or major amputation.
Conditions Studied
Interventions
- DEVICE MicroStent and Standard PTA
- DEVICE Standard PTA
Study Locations (20)
Florida
- Palm Vascular - Fort Lauderdale
- First Coast Cardiovascular Institute - Jacksonville
- FHV Health - Leesburg
- Mount Sinai Medical Center - Miami Beach
- Advent Health Sebring - Sebring
New Jersey
- Deborah Heart and Lung Center - Browns Mills
- North Jersey Vascular Center - Clifton
- AMI Vascular Institute - Galloway
Alabama
- Cardiovascular Associates of the Southeast - Birmingham
Arizona
- Copper State Vascular - Mesa
California
- St. Helena Hospital - St. Helena
Colorado
- Rocky Mountain Regional VA Medical Center - Aurora
Iowa
- Vascular Institute of the Midwest - Davenport
Louisiana
- Cardiovascular Institute of the South - Houma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2020-03-31 |
| Est. Completion | 2028-03 |
| Phase | NA |
What the registry record for NCT03477604 still lists
NCT03477604 is an interventional study that assigns participants to a tested intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, below the 4,204-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 2 interventions - of which MicroStent and Standard PTA is the first listed.
NCT03477604 names 20 study sites across 14 states, led by Florida, New Jersey, Alabama.
Frequently Asked Questions
What is clinical trial NCT03477604 about?
NCT03477604 is a clinical study titled "A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)". Randomized multicenter clinical trial consisting of two arms; one arm treated with PTA plus the MicroStent® System and one arm treated with PTA alone. Purpose to evaluate the safety and effectiveness of using the MicroStent® Peripheral Vascular Stent System, hereafter referred to as the MicroStent® ...
What is the current status of trial NCT03477604?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 177 participants. The study started on 2020-03-31. Estimated completion is 2028-03.
What conditions does trial NCT03477604 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT03477604?
The interventions under investigation include: MicroStent and Standard PTA (DEVICE), Standard PTA (DEVICE).
Who is sponsoring clinical trial NCT03477604?
This trial is sponsored by Micro Medical Solution, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03477604 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03477604's enrollment target sits among peer trials
177 27th of 79 higher than 53 of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
-
Prehabilitation and Rehabilitation in PAD
RECRUITING · NA
-
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
RECRUITING · NA
-
Assessment of the Utility of the Pantheris Small Vessel (SV) System
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491551 · 177 participants · NA
Alcohol-ROC-Training
- NCT06108050 · 177 participants · Phase 1
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- NCT06575712 · 177 participants · NA
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
- NCT06674980 · 177 participants · NA
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI